Biogen Makes Counterintuitive Move To Tap Exelixis’s George Scangos As CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
After a day of rumors, leadership changes leave both Biogen Idec and Exelixis with new chief executives as the high-profile companies face major questions about their futures.
You may also be interested in...
Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
Exelixis Stays The Course Under New Leadership of Michael Morrissey
As the R&D chief transitions to CEO, he sees no huge strategic shifts for Exelixis, though it "has had a tough six months."